Plasma clearance of an antibody--enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo. by Rogers, G. T. et al.
British Journal ofCancer(1995) 72, 1357-1363
© 1995 Stockton Press All rights reserved 0007-0920/95 $12.00
Plasma clearance of an antibody-enzyme conjugate in ADEPT by
monoclonal anti-enzyme: its effect on prodrug activation in vivo
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Summary The effect of anti-enzyme antibody clearance on prodrug turnover in antibody-directed enzyme
prodrug theray (ADEPT) has been studied. Mice bearing LS174T xenografts were given localising carboxypep-
tidase G2 (CPG)2 conjugate (AEC) and 19 h later galactosylated anti-CPG2 antibody (SB43-GAL). In regimen
I prodrug was injected 5 h after SB43-GAL as previously described. In regimen 2 and 3 a shortened and
extended clearance time was used in which prodrug was administered 0.5 h or 53 h after SB43-GAL
respectively. Regimen 1 resulted in similar tumour and normal tissue levels of active drug to those of the
control in which prodrug was given 72 h after AEC. SB43-GAL therefore accelerated clearance of enzyme
allowing early administration of prodrug. In regimen 2, very high active drug levels were found in the liver,
showing removal ofAEC from the blood followed by reactivation of enzyme and extensive and rapid prodrug
turnover. Active drug levels in tumour and blood reached similar peak levels to those of the control. Regimen
3 resulted in lower active drug levels in tissues, consistent with degradation and excretion of enzyme. Regimen
3 also produced the best tumour to normal ratios for active drug. Residual prodrug in tumour was unaffected
by SB43-GAL, showing the advantage of galactosylation in minimising inactivation of CPG2 in tumour. By
contrast, residual prodrug in blood persisted for longer when SB43-GAL was used. Circulatory clearance of
enzyme with SB43-GAL allows prodrug to be administered expediently with reduced toxicity and with the
prospect of increasing the dosage.
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The generation of cytotoxic agents from prodrugs selectively
in tumour tissue would be an important step forward in the
chemotherapy of cancer (Bagshawe, 1987; Bagshawe et al.,
1988). Monoclonal antibodies against a tumour marker could
provide the essential targeting agent to carry the means to
effect prodrug activation and result in accumulation of active
drug in tumour cells. Such a strategy would overcome the
various pharmacokinetic constraints of targeting monoclonal
antibodies (Jain, 1991) when they are directly coupled to the
drug or toxin. Generated active drug would be free to diffuse
into surrounding cancer cells, without the need for antibody
internalisation, and this would address the problem of
tumour antigen heterogeneity. Antibody-directed enzyme
prodrug therapy (ADEPT) aims at this goal (Bagshawe et al.,
1988; Senter et al., 1988) and depends on the selective bin-
ding of an antibody-enzyme conjugate by tumour followed
by enzymic conversion of the prodrug to the cytotoxic species.
This approach has been successfully tested by measuring
tumour growth delay in mice bearing choriocarcinoma
(Springer et al., 1991) or colon tumour xenografts (Sharma et
al., 1991; Blakey et al., 1993) using the prodrug 4-[(2-chloro-
ethyl)(2-mesyloxyethyl)amino]benzoyl-L-glutamate, which is
deglutamylated to a cytotoxic benzoic acid mustard by the
bacterial enzyme carboxypeptidase G2 (CPG2). The conjug-
ate, consisting of CPG2 coupled to either anti-hCG or anti-
CEA antibodies, was injected at least 3 days before the
prodrug to avoid toxicity due to turnover by residual enzyme
conjugate in the blood. The use of ADEPT has enabled a
2-fold higher concentration of active drug in tumour to be
achieved (over the concentration time curve 5-60 min) com-
pared with that obtained by direct drug administration
(unpublished data). The therapeutic efficiency and specificity,
however, are still limited owing to conversion of prodrug in
normal tissues by residual enzyme conjugate. Further decay
of enzyme activity from normal tissues takes place after 3
days, but this is also accompanied by loss of enzyme con-
jugate from the tumour site. A three-phase ADEPT system
incorporating an enzyme clearance stage has therefore been
developed and greatly reduces circulatory residual enzyme
and the toxicity that ensues (Sharma et al., 1990). In this
approach a galactosylated anti-CPG2 monoclonal antibody
(SB43-GAL) capable of inactivating the enzyme was injected
19 h after the conjugate and before the prodrug which was
given at 24 h. Residual enzyme conjugate reacted with the
anti-enzyme clearing antibody aiding its removal to the liver
and allowing prodrug to be administered earlier. Although
SB43-GAL effectively reduced the concentration of conjugate
in blood, its effect on the biodistribution of the conjugate in
other tissues and the rate of prodrug turnover is unknown. It
is important to optimise this in favour of tumour site-specific
prodrug activation especially if short half-life, more reactive,
drug species are employed. In the studies reported here we
have employed three different regimens using the monoclonal
anti-CPG2 clearing antibody (SB43) to investigate its effect
on in vivo generation of active drug in tissues of mice bearing
the colon tumour xenograft LS174T and given anti-CEA-
CPG2 localising conjugate.
Materials and methods
Conjugate and antibodies
Anti-CEA-carboxypeptidase G2 conjugate CPG2, a folate-
depleting bacterial enzyme was covalently coupled to the
F(ab')2 fragment of the anti-CEA monoclonal antibody
A5B7, employing a stable thioether linkage as described by
Melton et al. (1993). Enzymic activity was determined by the
spectrophotometric assay as described by McCulloch et al.
(1971).
Antibodies SB43, an IgG, anti-CPG2 monoclonal antibody,
was raised in Balb/C mice immunised with 50 lg of CPG2
and has been shown to inhibit the enzyme activity of CPG2
in vitro (Sharma et al., 1990). SB43 was galactosylated ac-
cording to a modification of the method of Mattes (1987).
Briefly, cyanomethyl tetra-O-acetyl-1-thiogalactopyranoside
(400 mg) was reacted with sodium methoxide (5.4 mg) in
anhydrous methanol at 20°C for 48 h. SB43 in 0.25 M sodium
borate buffer, pH 8.5, was added to the galactose derivative
(10 gg of derivative to 200fg of SB43) after evaporation of
the methanol. After shaking at 20°C for 2 h the galacto-
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sylated antibody was dialysed against three changes of phos-
phate-buffered saline (PBS).
Drugs
The prodrug 4-[bis(2-chloroethyl)amino]benzoyl-L-glutamic
acid was synthesised by reaction of benzoic acid mustard
chloride (Ross et al., 1955) with L-glutamic acid dibenzyl
ester (Bachem), followed by catalytic hydrogenation (Pd/C).
This prodrug is readily cleaved by CPG2 to the parent mus-
tard 4-[bis(2-chloroethyl)amino]benzoic acid (Springer et al.,
1990). This prodrug-active drug pair was chosen for this
study since they are stable at 0°C in aqueous media and can
be efficiently and reproducibly extracted from tissues at this
temperature. The chemical half-lives at 37C in PBS (pH 7.4)
for the prodrug and parent drug are 26 h and 10 h respec-
tively (Antoniw et al., 1990).
In vivo studies
These were carried out in Nu/Nu mice bearing the human
colon adenocarcinoma xenograft LS174T using tumours
between 0.08 and 0.4 g. Typically, mice were injected (i.v.)
with 50 units of A5B7-F(ab')2-CPG2 conjugate and given
prodrug (i.p., 400 mg kg-') 72 h later. In mice receiving anti-
enzyme clearing antibody three regimens were employed in
which SB43-GAL was given 19 h after the conjugate. In
regimen 1 prodrug was given (i.p. 400 mgkg-') at 5 h after
SB43-GAL as in the standard protocol. In regimens 2 and 3
a shortened and extended clearance time was used respec-
tively where prodrug was administered 0.5 h, or 53 h after
the SB43-GAL. In these mice sufficient SB43-GAL (usually
250jig) was administered intravenously to lower the blood
enzyme concentration to <0.1 unitsml-. The prodrug was
prepared for injection by dissolving in 10% dimethyl sulph-
oxide (DMSO) in sodium bicarbonate solution (1.2%).
Groups of 4-6 mice were killed at 5, 15, 30, 60 and 120 min
after the prodrug injection and the tissues (tumour, blood,
liver, kidney, lung and spleen) collected in preweighed tubes
and stored at - 70°C.
Drug extraction procedure
The frozen tissues were immersed in 2 ml of 2% hydrochloric
acid containing 0.25% sodium dodecyl sulphate (SDS) to
denature any residual enzyme and quickly cut up into small
pieces while still immersed, to form a fine suspension. A
homogenate was formed by grinding with a spatula and then
sonicated for 75 s while cooling in ice. The sonicate was
centrifuged at 3500 r.p.m. for 30 min and the supernatant put
through a prewashed (3 ml of methanol and 10 ml of 2 mM
hydrochloric acid) C18 Sep-Pak column (Waters Associates,
UK). This was washed with 2 mM hydrochloric acid (3 ml)
and the bound drugs eluted with methanol (BDH, HiPerSolv,
3 ml). The samples were dried in vacuo and reconstituted in
0.25 ml of mobile phase (see below) before analysis by high-
performance liquid chromatography (HPLC). Extraction
recoveries were >80% for the prodrug and >90% for the
active drug, similar to those in our previous study (Antoniw
et al., 1990) employing lower doses of prodrugs.
Tests were carried out to quantitate possible prodrug turn-
over by enzyme present in tissues and also possible hydrolysis
of the chlorine atoms after removal of tissues from the mice.
This was done by portioning tissues and keeping aliquots at
-70°C and immersed in ice for 24 h until the drugs were
extracted. There was no significant difference in extractable
residual prodrug or active drug in this experiment. Moreover,
the peak areas for the hydrolysis products were unchanged
although these were negligible compared with those of the
intact drugs being studied. Tissues which were kept at 37°C,
however, showed a reduction in the concentration ofprodrug
(approximately 18%) and increased amounts of the hydro-
lysis products, which were identified by their short retention
times (<3 min). Studies by Antoniw et al. (1990) are in
agreement, showing negligible prodrug turnover at the in
vitro stage following the extraction procedure described
above.
HPLC analysis was performed using a Waters system. This
consisted of a model 600A solvent pump, a Wisp 712 autoin-
jector and a model 480 variable wavelength detector set at
305 nm. The separation was performed on a Waters C18
Bondapak column (100 x 5mm, 5ltm particle size) with a
guard column of pellicular C18 material. The mobile phase
was 35% acetonitrile in water containing 1% acetic acid. The
retention times for the prodrug and active drug were 4.9 and
12.3 min respectively when the flow rate was set at 1 ml
min-'. Standard lines for both drugs were determined using
mouse serum spiked with drug standards and extracted as
described above. Peak areas were computed using Maxima
(Millipore) or EZChrom (Scientific Software) chromato-
graphy data systems. Drug concentrations are expressed as
tgg-' of tissue. Tissues from individual mice were extracted
separately and the mean data/group calculated together with
the percentage coefficient of variation. The drug concentra-
tions in the xenografts were found to be independent of the
tissue size and weight.
Results
Regimen 1: 5 h clearance time
The standard protocol for using SB43-GAL clearance has
been to give this 19 h after the enzyme conjugate when
sufficient SB43-GAL was administered to reduce circulatory
enzyme levels to <0.1 unitsml-' of blood (Sharma et al.,
1994). Prodrug was then administered at 20 or 24 h after the
conjugate without toxicity. In regimen 1 prodrug was injected
i.p. 24 h after the conjugate at a dose of 400 mg kg-'. The
concentrations of generated active drug measured in blood,
liver and tumour for this regimen are shown in Figure 1.
Prodrug was converted most efficiently in the liver where the
peak concentration of active drug reached 340figg'I at
15 min after injection. The peak concentrations of active
drug in tumour and blood, reaching 140figg-' and 199ltg
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Figure 1 Tissue concentrations of generated active drug in
regimen 1. Mice were given A5-CPG2 followed by SB43-GAL at
19h and prodrug (400mgkg-') at 24h 0, Blood; 0, liver; A,
tumour. Each data point is the mean from 4-6 mice and the
coefficient of variation between groups ofmice ranged from 9.4%
to 21.4% for blood, from 11.2% to 18.3% for liver and from
4.4% to 14.5% for tumour. Error bars on the graphs have been
excluded for clarity.
lr----i
e 0%0%0g-I respectively, were appreciably lower than that in the
liver. At time points beyond 5 min these levels are broadly
equivalent to those of the control where prodrug was
administered 72 h after the conjugate without SB43-GAL,
Figure 2. Here the peak concentrations of active drug in the
liver, tumour and blood reached 350, 160 and 210tLgg-1
respectively. At the 5min time point, however, SB43-GAL
resulted in lower active drug levels in blood and liver com-
patible with a slower rate of prodrug turnover. To give
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Figure 2 Tissue concentrations of generated active drug in con-
trol mice given prodrug 72 h after A5-CPG2. 0, Blood; 0, liver;
A, tumour. Each data point is the mean of 4-6 mice with the
coefficient of variation ranging from 16% to 28% for blood,
from 12.9% to 40% for liver and from 8% to 16% for tumour.
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prodrug safely at 24 h after the conjugate without SB43-GAL
necessitated using a lower dose (a dose of 200 mg kg' of
prodrug was used for these experiments) and the extrapolated
peak values for the active drug in liver, tumour and blood
were similar to those when SB-43-GAL was used (data not
shown). Regimen 1, although allowing early administration
of prodrug, resulted in marginally poorer tumour-blood and
tumour-liver ratios for active drug at time points up to
60min (Figure 3). There was also no obvious improvement
in the availability of active drug at the tumour site at the
time points studied, compared with the 72 h control.
Regimen 2: 0.5 h clearance time
An experiment was carried out in which prodrug was admini-
stered 0.5 h after the SB43-GAL and the tissue levels of
generated active drug measured, (Figure 4). Compared with
the control, Figure 2, there was a reduced concentration of
active drug in the blood (approximately 50% of that in the
control) up to 30 min after injection, although there was also
a reduction associated with the tumour which was severe up
to 5 min after injection of the prodrug. This resulted in
slightly poorer tumour-blood ratios (Figure 5a). Liver levels
of active drug, in contrast, were much higher than the con-
trol and tumour-liver ratios for active drug were poor
(Figure Sb).
Regimen 3: 53 h clearance time
Increasing the SB43-GAL clearance time to 53 h (prodrug
administered 72 h after the conjugate) resulted in the lowest
concentrations of active drug in the tissues, Figure 6. For
example, the peak concentration of active drug associated
with the tumour was over 60% lower than the corresponding
levels of the 72 h control. However, when SB43-GAL was
used, active drug concentrations in tumour were higher at
most time points than the five normal tissues selected for this
study. Comparative tumour-normal tissue ratios are shown
in Figure 7.
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Figure 3 Tumour-blood (a) and tumour-liver (b) ratios for active drug generated from prodrug in mice given A5-CPG2 followed
by SB43-GAL at 19 h and by prodrug at 24 h (regimen 1) compared with similar data for the control in which prodrug was given
72 h after the A5-CPG2.
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Residualprodrug
The data for the residual prodrug remaining in tissues for the
three clearance regimens (Figure 8) is consistent with the
clearance of conjugate from the blood to the liver. Thus, in
regimen 1 (Figure 8a) measurable prodrug in blood remained
up to 1 h after injection and the concentration of prodrug in
the liver also remained high up to 30 min after injection. In
mg kg-')
Time after prodrug injection (min)
Figure 4 Tissue concentrations of generated active drug in mice
given A5-CPG2 followed by SB43-GAL at 19 h and prodrug
(400mgkg-') at 19.5h (regimen 2). 0, Blood; E, liver; A,
tumour: Each data point is the mean of 4-6 mice with the
coefficient of variation ranging from 11.9% to 18.9% for blood,
from 10.5% to 20% for liver and from 5.2% to 9.2% for
tumour.
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regimen 2 (Figure 8b), however, rapid transport of conjugate
from the blood to the liver resulted in similar residual pro-
drug in blood but a much reduced level in the liver due to
extensive prodrug turnover. Regimen 3 resulted in the highest
concentration of residual prodrug in both blood and liver
(Figure 8c). Residual prodrug in the tumour was not altered
by SB43-GAL clearance and was depleted at a similar rate in
all regimens.
Discussion
The anti-carboxypeptidase G2 monoclonal antibody (SB43)
was developed to reduce the concentration of circulating
antibody enzyme conjugate in ADEPT. Our previous studies
(Sharma et al., 1990) demonstrated that SB43 could bind to
carboxypeptidase G2, causing loss of enzyme activity and as
such should be an ideal agent to quell circulating enzyme and
blood-borne activation of prodrug. To reduce possible inac-
tivation of enzyme at the tumour site, SB43 was covalently
linked to galactose to facilitate its rapid uptake by receptors
in the liver and minimise the circulatory dwell time. Given to
mice bearing the LS174T colon tumour xenograft 19 h after
the conjugate, SB43 linked to galactose had the predicted
effect of reducing CPG2 concentrations in the blood without
appreciably affecting the concentration of enzyme at the
tumour site (Sharma et al., 1990, 1991, 1994). This regimen
allowed therapy doses of prodrug to be injected within 24 h
ofgiving the conjugate. Using the above protocol (regimen 1)
the present studies have confirmed that SB43-GAL enables
prodrug to be administered 24 h after the conjugate without
toxicity and without appreciably altering the concentration of
active drug found in the tumour. Consistent with this, our
data for regimen 1 also shows an overall lower concentration
of active drug in blood at the 5 min time point together with
a higher level of residual prodrug compared with the control
(data not shown). Moreover, at later time points, active drug
levels in blood were similar to the 72 h control. This suggests
that SB43-GAL had the predicted effect of reducing blood
enzyme and reducing the rate ofcirculatory prodrug turnover
at 24 h after administration of the conjugate, to a level
similar to that at 72 h when SB43-GAL was not used. The
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Figure 5 Tumour-blood (a) and tumour-liver (b) ratios for active drug generated from prodrug in mice given A5-CPG2 and
SB43-GAL according to regimen 2 compared with active drug ratios for the control in which prodrug was given 72 h after
A5-CPG2-
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-.logistical advantage of this has been demonstrated in experi-
mental therapy studies (Sharma et al., 1991, 1994) and SB43-
GAL has been applied in clinical investigations in which,
given as an infusion, it successfully reduced plasma enzyme
concentrations and toxicity (Bagshawe et al., 1991). Anti-
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enzyme clearance is therefore a viable approach which has
been similarly applied for the circulatory clearance of
cytosine deaminase immunoconjugate (Kerr et al., 1993). It
therefore supplements other recently described clearance
systems including modification of conjugates with sugars
b
Time after prodrug injection (min)
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A5-CPG2 SB43 Prodrug (400 mg kg-')
0 72 h
A5-CPG2 Prodrug (400 mg kg-1)
Figure 6 Tissue concentrations ofgenerated active drug (a) in mice given A5-CPG2 followed by SB43-GAL at 19 h and prodrug at
72 h (regimen 3) and (b) in mice given A5-CPG2 and prodrug only. 0, blood; 0, liver; A, tumour; O, kidney; V, lung; *, spleen.
Each data point represents the mean 4-6 mice with the coefficient of variation ranging from 6% to 14.6% for blood; from 8% to
19.9% for liver, from 10% to 17% for tumour and from 3% to 18.6% for kidney, lung and spleen.
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(Sharma et al., 1994), use of anti-idiotypes or second
antibodies (Pedley et al., 1989) and use of biotin-avidin
constructs (Paganelli et al., 1991).
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Figure 8 Concentrations of residual prodrug in blood (0), liver
(0) and tumour (A) of mice given A5-CPG2 followed by SB43-
GAL at 19 h and prodrug at (a) 24 h, (b) 19.5 h and (c) 72 h. The
data represent the mean of 4-6 mice. The coefficient of variation
for all the groups ranged from 4.1% to 26%.
Depletion of residual prodrug from the liver is somewhat
faster when SB43-GAL anti-enzyme clearance is used, sug-
gesting that SB43-enzyme conjugate complexes in this organ
are capable of dissociation, thus supplementing enzyme
activity already present in the liver. This appears not to be a
problem when regimen 1 is used since the level of active drug
in liver appears to be similar to that of the control. Thus,
within the 5 h clearance time, free SB43-GAL can cause
progressive inactivation of conjugate and facilitate its degra-
dation and excretion. It is important to note that prodrug
turnover at the tumour site is not improved by earlier
administration of prodrug. An improvement might have been
expected owing to the higher concentration of localised
enzyme at 24h (Sharma et al., 1990), however, pharmaco-
kinetic studies to address this question (unpublished data)
have shown that prodrug turnover in tumour is more likely
to be limited by prodrug availability rather than an
insufficient concentration of targeted enzyme.
Further insight into the mechanism of SB43-GAL clear-
ance can be inferred from the study in which prodrug turn-
over was examined within half an hour of the SB43-GAL
injection (regimen 2). Here, in contrast to the standard
regimen, levels of active drug associated with the liver are
several-fold higher than that of the control. This is consistent
with effective clearance of anti-enzyme-enzyme complexes
via galactose receptor-mediated uptake to the liver and
subsequent dissociation, thus reactivating the enzyme. Exten-
sive turnover of prodrug would then be expected leading to
the observed high active drug levels. Moreover, this regimen
showed the fastest depletion of prodrug in the liver, resulting
in a much lower peak concentration compared with regimen
1 (Figure 8b). In contrast to the liver, the disappearance of
residual prodrug in the blood was markedly slower, consis-
tent with effective and rapid removal of enzyme from this
tissue. These results show that while anti-enzyme can remove
circulating enzyme to advantage in ADEPT, binding to the
enzyme is reversible in the liver and could lead to undesirable
feedback of active drug into the blood. It appears, however,
that enzyme complexes are also capable of degradation and
excretion within a period of hours (see regimen 1) and conse-
quently timing of prodrug administration is a key factor for
the optimisation of ADEPT.
In the third study (regimen 3) prodrug was administered 3
days after the conjugate (53 h after SB43-GAL). Under these
conditions the concentration of active drug associated with
all tissues was lower. For example, the concentration of
active drug in the tumour peaked at 60figg-, about two
and a half times lower than that of the control. This was
expected as the concentration of A5-CPG2 would be
decreased by the combined effects of SB43-GAL-accelerated
clearance and natural decay of the conjugate. However, at
most time points, there was more active drug in the tumour
than in the normal tissues, showing that prodrug turnover at
this site was favoured. With the prospect of increasing the
dosage of prodrug in regimen 3 it should still be possible to
attain a higher level of active drug in tumour by ADEPT
than by direct administration of the active drug.
Residual prodrug levels in the tumour were not affected by
SB43-GAL in all three regimens (Figure 8a, b and c). This
was expected, as our earlier studies (Sharma et al., 1994)
showed that the galactose moiety caused rapid removal of
conjugate from the blood, leaving the targeted enzyme at the
tumour site largely unaffected. The lower active drug levels in
tissues for regimen 3 (compared with regimens 1 and 2) are
consistent with a more complete clearance and degradation
of enzyme activity over the extended time interval.
It can be concluded from our investigations that anti-
enzyme modified by galactose-mediated clearance is useful in
reducing circulatory prodrug turnover. As such it enabled
prodrug to be administered expediently with reduced toxicity
and with the prospect of increasing the dosage. SB43-GAL-
CPG2 complexes are also capable of dissociation after their
clearance from the blood, leading to increased prodrug turn-
over and very high levels of active drug in the liver. Possible
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feedback of active drug into the blood, however, may be
controlled by appropriate timing of the prodrug injection. In
addition, our data suggest that an extended anti-enzyme
clearance schedule may enable much larger doses of prodrug
to be used with improved tumour site-specific turnover.
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